中国生物工程杂志

［1］ 王秀贞, 吴军, 孟宪军. 长效多肽药物研究进展. 中国生物工程杂志, 2003, 23(10):23～27 Wang X Z, Wu J, Meng X J. China Biotechnology, 2003,23(10):23～27 ［2］ Subramanian M G, Fiscella M, LamouséSmith A, et al. Albinterferonα2b:a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol, 2007,25(12):1411～1419 ［3］ Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today, 2005, 10 (21):1451～1458 ［4］ Stigsnaes P, Frokjaer S, Bjerregaard S, et al. Characterisation and physical stability of PEGylated glucagon. Int J Pharm, 2007, 330(12):89～98 ［5］ 张兵, 邹文艺, 范清林,等. 长效重组药物研究进展. 生物学杂志, 2008, 25(3):9～12 Zhang B, Zou W Y, Fan Q L, et al. Journal of Biology, 2008, 25(3):9～12 ［6］ 戚楠, 马清钧. 长效重组蛋白药物的研究进展. 中国生物工程杂志, 2006, 26(2):79～82 Qi N, Ma Q J. China Biotechnology, 2006, 26(2):79～82 ［7］ Duttaroy A, Kanakaraj P, Osborn L B, et al. Development of a longacting insulin analog using albumin fusion technology. Diabetes, 2005, 54(1):251～258 ［8］ Chen J Q, Bai G, Cao Y, et al. Onestep purification of a fusion protein of glucagonslike peptide1 and human serum albumin expressed in Pichia pastoris by an immunomagnetic separation technique. Biosci Biotechnol Biochem, 2007, 71(11):2655～2662 ［9］ Müller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem, 2007, 282(17):12650～12660 ［10］ 王磊, 何剑, 肖卫华. 人干扰素α2b和IgGFc片段融合蛋白显著延长体内半衰期. 生物工程学报, 2008,24(1):53～62 Wang L, He J, Xiao W H. Chin J Biotech, 2008, 24(1):53～62 ［11］ 王宇新, 周晓巍, 党颖, 等. 提高蛋白质和多肽类药物代谢稳定性的研究进展. 生物技术通讯, 2005,16(6):665～667 Wang Y X, Zhou X W, Dang Y, et al. Letters in Biotechnology, 2005,16(6):665～667 ［12］ Chan Y P, Meyrueix R, Kravtzoff R, et al. Review on Medusa(R): a polymerbased sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv, 2007, 4(4):441～451 ［13］ 付慧君. 抗蛋白酶降解肽类药物的结构修饰研究进展. 国外医学药学分册, 2006,33(4):269～271 Fu H J. Foreign Medical Sciences of Pharmacy, 2006,33(4):269～271 ［14］ Markert Y, Koditz J, Mansfeld J, et al. Increased proteolytic resistance of ribonuclease A by protein engineering. Protein Eng, 2001, 14(10):791～796 ［15］ 傅一鸣, 王清明, 安利国. 蛋白质和多肽药物长效性研究进展. 生命科学,2008,20(2): 258～262 Fu Y M, Wang Q M, An L G. Chinese Bulletin of Life Sciences, 2008, 20(2): 258～262 ［16］ Keyt B A, Paoni N F, Refino C J, et al. A fasteracting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A, 1994, 91(9):3670～3674 ［17］ Pepinsky R B, Lepage D J, Gill A, et al. Improved pharmacokinetic properties of a polyethylene glycolmodified form of interferonβla with preserved in vitro bioactivity. J Pharmacol Ex PTher. 2001, 297(3):1059～1066 ［18］ Glue P, Fang J W S, RouzierPanis R, et al. Pegylated interferonα2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther, 2000, 68(5):556～567 ［19］ Halpern W, Riccobene T A, Agostini H, et al. Albugranin, a recombinant human granulocyte colony stimulating factor (GCSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res, 2002, 19(11):1720～1729